# Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis

> **NCT05267262** · PHASE2 · COMPLETED · sponsor: **River 3 Renal Corp.** · enrollment: 43 (actual)

## Conditions studied

- Alport Syndrome
- Focal Segmental Glomerulosclerosis

## Interventions

- **DRUG:** R3R01

## Key facts

- **NCT ID:** NCT05267262
- **Lead sponsor:** River 3 Renal Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-15
- **Primary completion:** 2025-05-21
- **Final completion:** 2025-08-19
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2025-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05267262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05267262, "Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05267262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*